IMDX at a glance
The past year
Chart−76.6% $1.57, close Nov 18
- From the highest close
- −79.1%
- Vs the 200-day average
- −64.8%
Short interest
History1.0M shares
- Of shares outstanding
- 3.13%
- Since the last report
- +8.0%
- Days to cover
- 5.1 days
- Settled
- Oct 30, 2026
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 13 – Nov 19
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
IMDX price history
Loading recent earnings…
Investment thesis
What must happen next
Transplant centers and payers increasingly treat molecular organ-rejection testing as a useful recurring monitoring tool, allowing IMDX’s focused category exposure to convert into commercial demand.HoldingMateriality: High
GAAP annual revenue increased from $0.958 million in FY2022 to $4.055 million in FY2025. If adoption holds, the company has a path from niche diagnostic capability to repeat testing revenue; if adoption fails, the revenue base is too small to support the company.
Watch: Transplant programs standardize on established competing molecular tests from CareDx or Natera instead of adopting IMDX’s offering.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue increased from $0.958 million in FY2022 to $4.055 million in FY2025.
Open source ↗The transplant-rejection testing model can carry attractive unit economics if reimbursement and lab execution remain favorable rather than becoming a low-margin testing service.StrengtheningMateriality: High
GAAP annual gross profit improved from negative $0.018 million in FY2022 to $2.298 million in FY2025. Gross economics determine whether incremental adoption can eventually fund commercialization instead of simply adding unprofitable volume.
Watch: Medicare or commercial payers reduce reimbursement rates, impose prior authorization, or deny coverage for the relevant tests.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit improved from negative $0.018 million in FY2022 to $2.298 million in FY2025.
Open source ↗IMDX must secure timely capital, partner support, or a major reduction in burn before liquidity constraints interrupt commercialization.WeakeningMateriality: Medium
Cash was $11.583 million at FY2025 year-end. Even a valid clinical product can be a poor equity outcome if the company runs out of runway before adoption reaches scale.
Watch: Capital markets remain closed to small, loss-making diagnostics companies, forcing highly dilutive equity issuance.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $11.583 million at FY2025 year-end.
Open source ↗Management must convert the focused diagnostics platform into operating leverage, because the current cost base is far too large for the existing revenue scale.WeakeningMateriality: Medium
GAAP annual operating loss improved from negative $61.041 million in FY2024 to negative $51.124 million in FY2025. If fixed costs fall or revenue scales without proportional spending, equity value can accrue; if not, growth will continue to consume cash.
Watch: IMDX must build a larger direct sales force, medical-affairs team, or billing infrastructure before transplant-test volume materializes.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating loss improved from negative $61.041 million in FY2024 to negative $51.124 million in FY2025.
Open source ↗The capital structure must be repaired in a way that lets common shareholders participate in any future diagnostics success rather than having creditors or new financiers capture the economics.WeakeningMateriality: Medium
Stockholders’ equity declined from positive $20.468 million at FY2023 year-end to negative $31.464 million at FY2025 year-end. For the stock, not just the product, to work, balance-sheet claims and dilution cannot absorb the value created by future test adoption.
Watch: Debt holders, preferred investors, or warrant holders receive terms that capture most of the upside from future commercialization.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Stockholders’ equity declined from positive $20.468 million at FY2023 year-end to negative $31.464 million at FY2025 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Transplant centers and payers increasingly treat molecular organ-rejection testing as a useful recurring monitoring tool, allowing IMDX’s focused category exposure to convert into commercial demand. If adoption holds, the company has a path from niche diagnostic capability to repeat testing revenue; if adoption fails, the revenue base is too small to support the company.
The transplant-rejection testing model can carry attractive unit economics if reimbursement and lab execution remain favorable rather than becoming a low-margin testing service. Gross economics determine whether incremental adoption can eventually fund commercialization instead of simply adding unprofitable volume.
IMDX must secure timely capital, partner support, or a major reduction in burn before liquidity constraints interrupt commercialization. Even a valid clinical product can be a poor equity outcome if the company runs out of runway before adoption reaches scale.
Management must convert the focused diagnostics platform into operating leverage, because the current cost base is far too large for the existing revenue scale. If fixed costs fall or revenue scales without proportional spending, equity value can accrue; if not, growth will continue to consume cash.
The capital structure must be repaired in a way that lets common shareholders participate in any future diagnostics success rather than having creditors or new financiers capture the economics. For the stock, not just the product, to work, balance-sheet claims and dilution cannot absorb the value created by future test adoption.
All standing thesis claims
Original report summary
IMDX is a high-risk option on molecular transplant-rejection testing becoming a payer-covered, recurring diagnostics business before the balance sheet forces value-destructive financing.
Bull case and bear case
Bull case and bear case for Insight Molecular Diagnostics
Where the evidence on Insight Molecular Diagnostics disagrees: Mixed on the latest evidence (Nov 17, 2026). Of its 5 thesis points, 1 strengthening, 1 holding and 3 weakening.
Bull case: what the evidence supports
Transplant centers and payers increasingly treat molecular organ-rejection testing as a useful recurring monitoring tool, allowing IMDX’s focused category exposure to convert into commercial demand.
The transplant-rejection testing model can carry attractive unit economics if reimbursement and lab execution remain favorable rather than becoming a low-margin testing service.
Bear case: what the evidence questions
IMDX must secure timely capital, partner support, or a major reduction in burn before liquidity constraints interrupt commercialization.
Management must convert the focused diagnostics platform into operating leverage, because the current cost base is far too large for the existing revenue scale.
The capital structure must be repaired in a way that lets common shareholders participate in any future diagnostics success rather than having creditors or new financiers capture the economics.
Thesis-Break Engine
Thesis-break watch · Insight Molecular Diagnostics
No break has crossed Insight Molecular Diagnostics’s thesis. Its break conditions are checked against every new filing as it lands.
Early warning
The break condition read on the trailing twelve months through Insight Molecular Diagnostics’s latest quarterly report, ahead of the annual figure it is written on.
- Revenue decline, trailing 12 months
Across all companies, this kind of early warning has happened 3,039 times before. Those stocks beat the market by a median of 1% over the next six months, and 32% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Insight Molecular Diagnostics filed an SEC 8-K on 2026-11-16: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Insight Molecular Diagnostics filed an SEC 8-K on 2026-09-21: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Insight Molecular Diagnostics filed an SEC 8-K on 2026-08-10: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Transplant programs standardize on established competing molecular tests from CareDx or Natera instead of adopting IMDX’s offering.
- Medicare or commercial payers reduce reimbursement rates, impose prior authorization, or deny coverage for the relevant tests.
- Capital markets remain closed to small, loss-making diagnostics companies, forcing highly dilutive equity issuance.
- IMDX must build a larger direct sales force, medical-affairs team, or billing infrastructure before transplant-test volume materializes.
- Debt holders, preferred investors, or warrant holders receive terms that capture most of the upside from future commercialization.
IMDX news
Loading headlines…
Financial statements
IMDX income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
IMDX: quick answers
- When does Insight Molecular Diagnostics (IMDX) report earnings next?
- Insight Molecular Diagnostics's next results are projected for February 15, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 16, 2026. Earnings calendar
- What is IMDX's short interest?
- As of October 30, 2026, 1.0M IMDX shares were sold short, 3.13% of its shares outstanding, up 8.0% from the count before. At the stock's average daily volume that is 5.1 days to cover. FINRA publishes the count twice a month. IMDX short interest history

